{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:33:10Z","timestamp":1783053190959,"version":"3.54.6"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jdin.2023.12.012","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T09:49:43Z","timestamp":1705830583000},"page":"165-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline Psoriasis Area and Severity Index from week 4 to 40"],"prefix":"10.1016","volume":"15","author":[{"given":"Richard G.","family":"Langley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiranjeev","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Situ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Alulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fareen","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Teneralli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barkha P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Disher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7549","key":"10.1016\/j.jdin.2023.12.012_bib1","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1136\/bmj.332.7549.1080","article-title":"The cost of dichotomising continuous variables","volume":"332","author":"Altman","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.jdin.2023.12.012_bib2","author":"Phillippo"},{"issue":"3","key":"10.1016\/j.jdin.2023.12.012_bib3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10201","key":"10.1016\/j.jdin.2023.12.012_bib4","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"10148","key":"10.1016\/j.jdin.2023.12.012_bib5","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"(2018) Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T03:39:38Z","timestamp":1717385978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328724000166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":5,"alternative-id":["S2666328724000166"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2023.12.012","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline Psoriasis Area and Severity Index from week 4 to 40","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2023.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}